PDF(Pubmed)
Abstract：
Tuberculosis (TB) is a chronic bacterial disease, as well as a complex immune disease. The occurrence, development, and prognosis of TB are not only related to the pathogenicity of Mycobacterium tuberculosis (Mtb), but also related to the patient\'s own immune state. The research and development of immunotherapy drugs can effectively regulate the body\'s anti-TB immune responses, inhibit or eliminate Mtb, alleviate pathological damage, and facilitate rehabilitation. This paper reviews the research progress of immunotherapeutic compounds for TB, including immunoregulatory compounds and repurposing drugs, and points out the existing problems and future research directions, which lays the foundation for studying new agents for host-directed therapies of TB.
摘要：
结核病（TB）是一种慢性细菌性疾病，以及复杂的免疫疾病。的发生,发展,结核病的预后不仅与结核分枝杆菌(Mtb)的致病性有关,也与患者自身的免疫状态有关。免疫治疗药物的研发可以有效调节机体的抗结核免疫应答,抑制或消除Mtb，减轻病理损伤，促进康复。本文就结核病免疫治疗化合物的研究进展作一综述。包括免疫调节化合物和再利用药物，指出了存在的问题和未来的研究方向，这为研究结核病宿主导向疗法的新药奠定了基础。
